<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002644</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064151</org_study_id>
    <secondary_id>NCRI-IBIS</secondary_id>
    <secondary_id>EU-94041</secondary_id>
    <secondary_id>UKCCCR-IBIS</secondary_id>
    <nct_id>NCT00002644</nct_id>
  </id_info>
  <brief_title>Tamoxifen for the Prevention of Breast Cancer in High-Risk Women</brief_title>
  <official_title>INTERNATIONAL BREAST CANCER INTERVENTION STUDY: A MULTICENTRE TRIAL OF TAMOXIFEN TO PREVENT BREAST CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
      tamoxifen may fight breast cancer by blocking the uptake of estrogen.

      PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of tamoxifen
      with a placebo in preventing breast cancer in women at high risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate whether tamoxifen taken daily for 5 years reduces the incidence of
      and mortality from breast cancer in high-risk women. II. Assess the risks and benefits of
      this intervention.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Participants are
      stratified by participating institution. Participants are randomly assigned to receive either
      oral tamoxifen or oral placebo every day for 5 years in the absence of breast cancer
      development or pregnancy. Participants are followed every 6 months for 5 years; then annually
      for 5 years. Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: 7,000 women will be entered at a rate of 200-500 women/institution/5
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: See General Eligibility Criteria

        PATIENT CHARACTERISTICS: Age: 35 to 70 Sex: Women only Menopausal status: Pre-, peri-, or
        postmenopausal Performance status: Not specified Life expectancy: At least 10 years
        Cardiovascular: No prior deep vein thrombosis Pulmonary: No prior pulmonary embolus Other:
        Psychologically and physically able to undertake therapy for 5 years No other medical
        condition more serious than risk of breast cancer No prior cancer except: Nonmelanomatous
        skin cancer In situ cancer of the cervix No pregnant women Effective nonhormonal
        contraception required of fertile women

        PRIOR CONCURRENT THERAPY: Hormone replacement therapy for menopausal symptoms allowed at
        lowest effective dose Not currently on tamoxifen Not currently on anticoagulants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Cuzick, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial Cancer Research Fund</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC2A 3PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Cuzick J, Edwards R. Drop-outs in tamoxifen prevention trials. Lancet. 1999 Mar 13;353(9156):930.</citation>
    <PMID>10094016</PMID>
  </reference>
  <results_reference>
    <citation>Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011 May 4;103(9):744-52. doi: 10.1093/jnci/djr079. Epub 2011 Apr 11.</citation>
    <PMID>21483019</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone J, Warren RM, Pinney E, Warwick J, Cuzick J. Determinants of percentage and area measures of mammographic density. Am J Epidemiol. 2009 Dec 15;170(12):1571-8. doi: 10.1093/aje/kwp313. Epub 2009 Nov 12.</citation>
    <PMID>19910376</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007 Feb 21;99(4):272-82.</citation>
    <PMID>17312304</PMID>
  </results_reference>
  <results_reference>
    <citation>Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. 2006 Aug 20;24(24):3991-6.</citation>
    <PMID>16921052</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004 Apr 21;96(8):621-8.</citation>
    <PMID>15100340</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002 Sep 14;360(9336):817-24.</citation>
    <PMID>12243915</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2004</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

